Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A bioequivalency study of novel levetiracetam extended release 1500 mg tablets under fasing/non fasting swithcover conditions in heathy subjects.

Next Previous
X
Search
Trial Profile

A bioequivalency study of novel levetiracetam extended release 1500 mg tablets under fasing/non fasting swithcover conditions in heathy subjects.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 05 May 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Levetiracetam (Primary)
  • Indications Myoclonic epilepsies; Partial epilepsies; Tonic-clonic epilepsy
  • Focus Pharmacokinetics

    • Most Recent Events

    • 05 May 2017 New trial record
    • 28 Apr 2017 Results assessing bioequivalence using patient data from this and other two trials (see CTPs 284435 and 284433), presented at the 69th Annual Meeting of the American Academy of Neurology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top